Literature DB >> 26782281

[Chronic rejection: Differences and similarities in various solid organ transplants].

H Suhling1, J Gottlieb2, C Bara3, R Taubert4, E Jäckel5, M Schiffer6, J H Bräsen7.   

Abstract

In this paper, chronic rejections after transplantation of the lungs, heart, liver, and kidney are described. Chronic allograft dysfunction (CAD) plays an important role in all of these transplantations and has a significant influence on patient survival. The pathophysiological reasons for CAD varies greatly in the various organs.Chronic lung allograft dysfunction (CLAD) is the most important determinant of survival and quality of life after lung transplantation. Diagnosis is based on lung function, especially forced expiratory flow in 1 s (FEV1) decline. Prevention, early detection, and rapid treatment are extremely important. Azithromycin and extracorporeal photopheresis are commonly used for treatment because they usually positively influence the progression of lung remodeling.The expression for chronic rejection of the heart is cardiac allograft vasculopathy (CAV). Immunological and nonimmunological factors are important for its development. Due to limited therapeutic options, prevention is of utmost importance (administration of mTOR inhibitors and minimizing cardiovascular risk factors).The mid- and long-term survival rates after liver transplantation have hardly changed in recent decades, which is an indication of the difficulty in diagnosing chronic graft dysfunction. Chronic ductopenic rejection accounts for a small proportion of late graft dysfunction. Idiopathic posttransplant hepatitis and de novo autoimmune hepatitis are important in addition to recurrence of the underlying disease that led to transplantation.Chronic allograft nephropathy is the result of severe rejection which cumulates in increasing fibrosis with remodeling. The earliest possible diagnosis and therapy is currently the only option. Diagnosis is based on evidence of donor-specific antibodies and histological findings.

Entities:  

Keywords:  Allograft vasculopathy; Autoimmune hepatitis; Chronic allograft dysfunction; Humoral rejection; Immunosuppression

Mesh:

Year:  2016        PMID: 26782281     DOI: 10.1007/s00108-015-3806-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  63 in total

Review 1.  Transplant capillaropathy and transplant glomerulopathy: ultrastructural markers of chronic renal allograft rejection.

Authors:  Bela Ivanyi
Journal:  Nephrol Dial Transplant       Date:  2003-04       Impact factor: 5.992

2.  Long-term health-related quality of life after lung transplantation: different predictors for different dimensions.

Authors:  Karin M Vermuelen; Wim van der Bij; Michiel E Erasmus; Elisabeth M TenVergert
Journal:  J Heart Lung Transplant       Date:  2007-02       Impact factor: 10.247

3.  Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data.

Authors:  Robert J Wong; Christina Chou; Clark A Bonham; Waldo Concepcion; Carlos O Esquivel; Aijaz Ahmed
Journal:  Clin Transplant       Date:  2014-04-19       Impact factor: 2.863

Review 4.  Liver biopsy interpretation for causes of late liver allograft dysfunction.

Authors:  Anthony J Demetris; Oyedele Adeyi; Chris O C Bellamy; Andrew Clouston; Frederic Charlotte; Albert Czaja; Ierachmiel Daskal; Magda S El-Monayeri; Paulo Fontes; John Fung; Bruno Gridelli; Maria Guido; Hironori Haga; John Hart; Eva Honsova; Stefan Hubscher; Tomoo Itoh; Nirag Jhala; Patricia Jungmann; Urmila Khettry; Charles Lassman; Saverio Ligato; John G Lunz; Amadeo Marcos; Marta Ida Minervini; Johan Mölne; Mike Nalesnik; Imad Nasser; Desley Neil; Erin Ochoa; Orit Pappo; Parmjeet Randhawa; Finn P Reinholt; Phil Ruiz; Mylène Sebagh; Marco Spada; Aurelio Sonzogni; Athanassios C Tsamandas; Annika Wernerson; Tong Wu; Funda Yilmaz
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

Review 5.  What is the long-term outcome of the liver allograft?

Authors:  Stefan G Hübscher
Journal:  J Hepatol       Date:  2011-03-21       Impact factor: 25.083

6.  Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression.

Authors:  Alida L P Caforio; Francesco Tona; Anna Belloni Fortina; Annalisa Angelini; Stefano Piaserico; Antonio Gambino; Giuseppe Feltrin; Angelo Ramondo; Marialuisa Valente; Sabino Iliceto; Gaetano Thiene; Gino Gerosa
Journal:  Am J Transplant       Date:  2004-06       Impact factor: 8.086

7.  Prognostic impact of microvasculopathy on survival after heart transplantation: evidence from 9713 endomyocardial biopsies.

Authors:  Nicola E Hiemann; Ernst Wellnhofer; Christoph Knosalla; Hans B Lehmkuhl; Julia Stein; Roland Hetzer; Rudolf Meyer
Journal:  Circulation       Date:  2007-08-20       Impact factor: 29.690

8.  Natural killer cells play a critical role in cardiac allograft vasculopathy in an interleukin-6--dependent manner.

Authors:  Zhu-Xu Zhang; Xuyan Huang; Jifu Jiang; Dameng Lian; Wei-Ping Min; Weihua Liu; Aaron Haig; Anthony M Jevnikar
Journal:  Transplantation       Date:  2014-11-27       Impact factor: 4.939

9.  Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.

Authors:  M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel
Journal:  Am J Transplant       Date:  2014-02       Impact factor: 8.086

10.  Conventional vs. tablet computer-based patient education following lung transplantation--a randomized controlled trial.

Authors:  Hendrik Suhling; Jessica Rademacher; Imke Zinowsky; Jan Fuge; Mark Greer; Gregor Warnecke; Jacqueline M Smits; Anna Bertram; Axel Haverich; Tobias Welte; Jens Gottlieb
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.